Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Etoposide
- Indications Bladder cancer; Neuroendocrine carcinoma; Prostate cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2019 Status changed from not yet recruiting to recruiting.
- 10 Aug 2018 Planned End Date changed from 27 Jun 2021 to 1 Sep 2021.
- 10 Aug 2018 Planned primary completion date changed from 27 Jun 2020 to 1 Sep 2020.